Skip to content
Clinical Trials – home
PolandBack to Poland

Clinical trials in Olsztyn – page 22

316 clinical trials in Olsztyn, Poland across 4 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

PolandOur site in PolandBadaniaKliniczne.pl(opens in a new tab)
Olsztyn at a glance
316
clinical trials
  • Research sites4
Type of trial
Recruitment status
Quick filters

316 trials in Olsztyn

Open in trial search

Bladder cancer

Not recruiting

Study on the Effectiveness and Safety of Durvalumab with Gemcitabine and Cisplatin for Patients with Muscle-Invasive Bladder Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:AstraZeneca AB

Ovarian cancer

Not recruiting

Study of Olaparib for Patients with Advanced BRCA-Mutated Ovarian Cancer After Initial Platinum-Based Chemotherapy

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Olaparib
  • Sponsor:AstraZeneca AB

Study of Pembrolizumab, Carboplatin, and Paclitaxel for Patients with Metastatic Squamous Non-small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of V940 and Pembrolizumab for Patients with Resected Stage II, IIIA, IIIB Non-Small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:MRNA-4157
  • Sponsor:Merck Sharp & Dohme LLC

Study on Axatilimab for Patients with Idiopathic Pulmonary Fibrosis

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Axatilimab
  • Sponsor:Syndax Pharmaceuticals Inc.

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Ovarian cancer stage IV+1

Not recruiting

Study of Niraparib and Dostarlimab Combined with Platinum Therapy for Newly Diagnosed Stage III or IV Non-mucinous Epithelial Ovarian Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Tesaro Inc.

Study of Pembrolizumab, Olaparib, and Pemetrexed for Patients with Stage IV Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Merck Sharp & Dohme LLC

Study of Relatlimab and Nivolumab with Chemotherapy for Patients with Stage IV or Recurrent Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study Comparing RBS-001 and Aflibercept for Patients with Neovascular Age-Related Macular Degeneration

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Rophibio Inc.

Study of Osimertinib and Chemotherapy for Patients with EGFR Mutation Positive Resectable Non-Small Cell Lung Cancer

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:AstraZeneca AB

Lupus nephritis

Not recruiting

Study on Anifrolumab for Adults with Active Lupus Nephritis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Anifrolumab
  • Sponsor:AstraZeneca AB

Other cities in Poland

The busiest research cities in the country

All 236 cities in Poland

Clinical research in Olsztyn

What the registry says about research in the country

01 Oncology Research

Clinical trials focusing on acute myeloid leukemia treatments and innovative therapies for various types of lung cancer. Studies include evaluation of new drug combinations and treatment approaches for colorectal cancer and lymphoma.

  • Advanced treatment combinations for leukemia
  • Targeted therapies for NSCLC
  • Novel approaches in lymphoma treatment

Research emphasizes personalized medicine approaches and improving patient outcomes in advanced stages of disease.

02 Dermatology Studies

Innovative research into plaque psoriasis and psoriatic arthritis treatments, including new biological therapies and novel drug combinations. Studies also examine treatments for rare conditions like pyoderma gangrenosum.

  • Biological therapy assessment
  • Chronic skin condition management
  • Combined treatment approaches

Focus on developing more effective treatments for moderate to severe skin conditions.

03 Cardiovascular Research

Studies examining new approaches to heart failure prevention and treatment, including investigations of novel drug combinations. Research focuses on reducing cardiovascular events and improving outcomes in high-risk patients.

  • Heart failure prevention strategies
  • Cardiovascular risk reduction
  • Therapeutic combinations

Emphasis on preventive measures and innovative treatment strategies for cardiac conditions.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.